Patients on both E/C/F / TAF ( n = 112 ) and E/C/F / TDF ( n = 58 ) had high rates of virologic suppression ( < 50 HIV copies per milliliter ) at week 24 ( 86.6 % ; 89.7 % ) and at week 48 ( 88.4 % ; 87.9 % ) , and had similar improvements in CD4 at week 48 ( 177 ; 204 ) , respectively .